These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 35125345)

  • 1. Multipathway In Vitro Pharmacological Characterization of Specialized Proresolving G Protein-Coupled Receptors.
    Merlin J; Park J; Vandekolk TH; Fabb SA; Allinne J; Summers RJ; Langmead CJ; Riddy DM
    Mol Pharmacol; 2022 Apr; 101(4):246-256. PubMed ID: 35125345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leukotriene B4/antimicrobial peptide LL-37 proinflammatory circuits are mediated by BLT1 and FPR2/ALX and are counterregulated by lipoxin A4 and resolvin E1.
    Wan M; Godson C; Guiry PJ; Agerberth B; Haeggström JZ
    FASEB J; 2011 May; 25(5):1697-705. PubMed ID: 21307335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resolvin D1 receptor stereoselectivity and regulation of inflammation and proresolving microRNAs.
    Krishnamoorthy S; Recchiuti A; Chiang N; Fredman G; Serhan CN
    Am J Pathol; 2012 May; 180(5):2018-27. PubMed ID: 22449948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of resolution sensor drives age-related cardiometabolic and cardiorenal defects and impedes inflammation-resolution in heart failure.
    Tourki B; Kain V; Pullen AB; Norris PC; Patel N; Arora P; Leroy X; Serhan CN; Halade GV
    Mol Metab; 2020 Jan; 31():138-149. PubMed ID: 31918915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resolvin D1 inhibits TGF-β1-induced epithelial mesenchymal transition of A549 lung cancer cells via lipoxin A4 receptor/formyl peptide receptor 2 and GPR32.
    Lee HJ; Park MK; Lee EJ; Lee CH
    Int J Biochem Cell Biol; 2013 Dec; 45(12):2801-7. PubMed ID: 24120851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural and conformational studies of biased agonism through formyl peptide receptors.
    Liao Q; Ye RD
    Am J Physiol Cell Physiol; 2022 May; 322(5):C939-C947. PubMed ID: 35385323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Annexin A1 interaction with the FPR2/ALX receptor: identification of distinct domains and downstream associated signaling.
    Bena S; Brancaleone V; Wang JM; Perretti M; Flower RJ
    J Biol Chem; 2012 Jul; 287(29):24690-7. PubMed ID: 22610094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New Advances in Targeting the Resolution of Inflammation: Implications for Specialized Pro-Resolving Mediator GPCR Drug Discovery.
    Park J; Langmead CJ; Riddy DM
    ACS Pharmacol Transl Sci; 2020 Feb; 3(1):88-106. PubMed ID: 32259091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA-181b regulates ALX/FPR2 receptor expression and proresolution signaling in human macrophages.
    Pierdomenico AM; Recchiuti A; Simiele F; Codagnone M; Mari VC; Davì G; Romano M
    J Biol Chem; 2015 Feb; 290(6):3592-600. PubMed ID: 25505240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterologously expressed formyl peptide receptor 2 (FPR2/ALX) does not respond to lipoxin A₄.
    Hanson J; Ferreirós N; Pirotte B; Geisslinger G; Offermanns S
    Biochem Pharmacol; 2013 Jun; 85(12):1795-802. PubMed ID: 23643932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for an anti-inflammatory loop centered on polymorphonuclear leukocyte formyl peptide receptor 2/lipoxin A4 receptor and operative in the inflamed microvasculature.
    Brancaleone V; Dalli J; Bena S; Flower RJ; Cirino G; Perretti M
    J Immunol; 2011 Apr; 186(8):4905-14. PubMed ID: 21398608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insights into the Activation Mechanism of the ALX/FPR2 Receptor.
    Schmitz Nunes V; Rogério AP; Abrahão O
    J Phys Chem Lett; 2020 Nov; 11(21):8952-8957. PubMed ID: 33030905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biased allosteric modulation of formyl peptide receptor 2 leads to distinct receptor conformational states for pro- and anti-inflammatory signaling.
    Zhang S; Gong H; Ge Y; Ye RD
    Pharmacol Res; 2020 Nov; 161():105117. PubMed ID: 32768626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual modulation of formyl peptide receptor 2 by aspirin-triggered lipoxin contributes to its anti-inflammatory activity.
    Ge Y; Zhang S; Wang J; Xia F; Wan JB; Lu J; Ye RD
    FASEB J; 2020 May; 34(5):6920-6933. PubMed ID: 32239559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proresolving lipid mediators resolvin D1, resolvin D2, and maresin 1 are critical in modulating T cell responses.
    Chiurchiù V; Leuti A; Dalli J; Jacobsson A; Battistini L; Maccarrone M; Serhan CN
    Sci Transl Med; 2016 Aug; 8(353):353ra111. PubMed ID: 27559094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specialized pro-resolving receptors are expressed in salivary glands with Sjögren's syndrome.
    Dos Santos HT; Nam K; Maslow F; Trump B; Baker OJ
    Ann Diagn Pathol; 2022 Feb; 56():151865. PubMed ID: 34847389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a novel recycling sequence in the C-tail of FPR2/ALX receptor: association with cell protection from apoptosis.
    Thompson D; McArthur S; Hislop JN; Flower RJ; Perretti M
    J Biol Chem; 2014 Dec; 289(52):36166-78. PubMed ID: 25326384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural basis of ligand binding modes at the human formyl peptide receptor 2.
    Chen T; Xiong M; Zong X; Ge Y; Zhang H; Wang M; Won Han G; Yi C; Ma L; Ye RD; Xu Y; Zhao Q; Wu B
    Nat Commun; 2020 Mar; 11(1):1208. PubMed ID: 32139677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ligand-specific conformational change of the G-protein-coupled receptor ALX/FPR2 determines proresolving functional responses.
    Cooray SN; Gobbetti T; Montero-Melendez T; McArthur S; Thompson D; Clark AJ; Flower RJ; Perretti M
    Proc Natl Acad Sci U S A; 2013 Nov; 110(45):18232-7. PubMed ID: 24108355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treating neutrophilic inflammation in COPD by targeting ALX/FPR2 resolution pathways.
    Bozinovski S; Anthony D; Anderson GP; Irving LB; Levy BD; Vlahos R
    Pharmacol Ther; 2013 Dec; 140(3):280-9. PubMed ID: 23880288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.